Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

gastro-oesophageal junction adenocarcinoma

- PMLiVE

AstraZeneca’s Imfinzi receives FDA approval for gastric and gastro-oesophageal cancers

In 2022, nearly one million new patients were diagnosed with gastric cancer

- PMLiVE

AstraZeneca’s Imfinzi granted FDA priority review to treat early-stage gastric cancer

Gastric cancer is the fifth leading cause of cancer-related deaths globally

- PMLiVE

Amgen’s bemarituzumab shows promise in phase 3 gastric cancer study

Almost one million new cases of gastric cancer are diagnosed globally every year

- PMLiVE

AstraZeneca announces promising late-stage results for Imfinzi in gastric cancer

Almost one million cases of the disease are diagnosed globally every year

- PMLiVE

BeiGene’s Tevimbra combination granted FDA approval to treat gastric cancer

Approximately 27,000 cases of the disease were diagnosed in the US in 2024

- PMLiVE

BeiGene’s Tevimbra approved by EC for first-line gastric and oesophageal cancer use

Gastric cancer is the fifth leading cause of cancer-related deaths globally and oesophageal cancer is the sixth

- PMLiVE

BeiGene’s Tevimbra recommended by CHMP for gastric and oesophageal cancer

Gastric cancer is the fifth leading cause of cancer-related deaths globally, while oesophageal cancer is the sixth

- PMLiVE

Astellas’ Vyloy approved by FDA as first-line gastric cancer combination treatment

Approximately 26,890 new cases of gastric cancer will be diagnosed in the US this year

- PMLiVE

Merck and Astellas/Pfizer’s bladder cancer combination receives MHRA approval

About 614,000 people are diagnosed with bladder cancer globally every year

- PMLiVE

Astellas and AviadoBio enter exclusive dementia gene therapy deal worth over $2bn

Frontotemporal dementia accounts for less than one in 30 cases of the neurodegenerative disorder

- PMLiVE

Astellas’ Vyloy combination approved by EC as first-line gastric cancer treatment

Approximately 136,000 cases of the disease are diagnosed in Europe every year

- PMLiVE

Merck and Astellas/Pfizer’s bladder cancer combination granted EC approval

Bladder cancer is the fifth most commonly diagnosed cancer in Europe, with more than 165,000 annual cases

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links